Syk activation is a key intermediate step in the activation of platelets by the physiologic agonist collagen. We have found that Syk is rapidly ubiquitinated upon activation of platelets by collagen, CRP and convulxin. The Src family kinase inhibitors prevented Syk phosphorylation and its ubiquitination, indicating that the process is downstream of Src kinases. The ubiquitination of Syk did not cause degradation of the protein as evidenced by the lack of effect of proteasomal and lysosomal inhibitors. We separated ubiquitinated Syk from its nonubiquitinated counterpart and used an in vitro kinase assay to compare their activities. We found that the ubiquitinated Syk appeared to be about five-fold more active. Using a phosphospecific antibody to Syk (Tyr525/Tyr526) that measures activated Syk, we found that the majority (60-75%) of the active Syk is in the ubiquitinated fraction. This result explains the apparent high specific activity of ubiquitinated Syk. In c-Cbl deficient mice, Syk is not ubiquitinated implicating c-Cbl as the E3 ligase involved in Syk ubiquitination. Furthermore, Syk is not dephosphorylated in these mice. We propose that c-Cbl plays a regulatory role in GPVI/FcRchain-dependent platelet activation through its interaction with Syk.
Introduction
The activation of platelets by collagen is an essential event in prevention of bleeding. 1 Collagen binds to at least two different receptors on the platelet membrane. One receptor is an integrin 2 1 that is primarily responsible for firm adhesion of platelets to collagen. 2 The other is the GpVI-FcR -chain complex that is responsible for the majority of the intracellular signaling events. 3, 4 Platelet activation by collagen leads to an increase in intracellular Ca 2+ and activation of protein kinase C. 5 The responses are dependent on the activation of phospholipase C 2 downstream of GpVI-FcR -chain activation. [6] [7] [8] While the details of signaling through this receptor are not complete, many aspects have been described and the pathways parallel activation by immune receptors in lymphocytes. [9] [10] [11] Initially the immunoreceptor tyrosine-based activation motif (ITAM) of the FcR -chain becomes phosphorylation by a Src family kinase, Fyn and/or Lyn. The tyrosine kinase Syk binds to the ITAM and becomes autophosphorylated. 12 Activation of Syk leads to phosphorylation of several adapter proteins such as LAT and SLP76, activation of PI-3 kinase, recruitment of Btk and ultimately activation of PLC 2 by tyrosine phosphorylation 13, 14 Activation of PLC 2 in vitro has been shown to depend on phosphorylation on at least two tyrosines. 8 c-Cbl is a multidomain adapter protein that is highly expressed in hematopoietic cells and has been shown to facilitate signal transduction in several signaling systems by juxtaposing specific proteins involved in signaling pathways. 15, 16 Thus c-Cbl binds to several proteins that are involved in platelet signaling, such as Src-and Syk-family protein tyrosine kinases and PI-3 kinase p85 subunit. [17] [18] [19] [20] Furthermore, c-Cbl is an important cofactor in ubiquitination, a covalent modification of proteins with one or several residues of ubiquitin. 16, 21 Ubiquitin is a small protein For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From of about 8.5 kDa that is synthesized as a polymer but cleaved before use. Ubiquitination is a tightly regulated process involving three distinct types of enzymes designated E1, E2 and E3.
Ubiquitin is attached to E1 via a thiolester bond. The interaction of E1 with E2 allows transfer of ubiquitin to a thiolester bond on E2. E3 assists in docking a target protein to E2 for ubiquitination on a lysine side chain. The complex of E2 and E3 can be thought of as a ligase that catalyzes the final reaction. c-Cbl has been shown to function as an E3 ligase primarily for activated protein tyrosine kinases including the kinases of the Src-and Syk-families. 16, [22] [23] [24] [25] [26] [27] Targeting proteins for proteasomal degradation has been recognized as a major role of ubiquitination. 16, 28, 29 The exact role of c-Cbl in platelet activation is not completely known. Oda et al. 30 showed that c-Cbl becomes phosphorylated when platelets are stimulated by recombinant thrombopoietin. Polgar et al. 31 showed that both convulxin and collagen induce phosphorylation of c-Cbl. Both c-Cbl phosphorylation and its association with PI-3 kinase were found to be dependent on fibrinogen receptor ( IIb 3) occupation. 32 c-Cbl also becomes tyrosinephosphorylated after platelet activation induced by Fc receptor engagement. 33 In c-Cbl knockout mouse platelets, phosphorylation of several proteins, including Syk, downstream of GPVI activation is enhanced when compared to wild type mice. 34 Platelet aggregation to the GPVI agonist, collagen related peptide (CRP), was also enhanced in knockout mice. In this study, we have determined that Syk is ubiquitinated in human and mouse platelets when they are stimulated by agonists that interact with GPVI. This ubiquitination is dependent on both c-Cbl and a Src family kinase, which is consistent with findings that c-Cbl ubiquitinates activated tyrosine kinases 17, 19, 26, 35 and that Src-family kinases are involved in the activation of Syk. 21, 36 Using an antibody specific for the activation loop of Syk, we conclude that the majority of 
Experimental Procedures

Materials
All reagents were from Sigma unless stated. Anti-phosphotyrosine (4G10) was from Upstate USA (Charlottesville, VA). Anti-Syk (4D10 and N19), anti-ubiquitin (P4D1), anti-c-Cbl (C-15), Protein A/G PLUS-agarose and HRP-conjugated goat anti-mouse or anti-rabbit IgG were from Santa Cruz (Santa Cruz, CA). Antiserum to the N-terminal SH2 domain of Syk was raised in rabbits using the corresponding GST-fusion protein. Anti-phosphospecific Syk (Tyr525/Tyr 526) was from Cell Signaling Technology (Beverly MA). Epoxomicin, MG-132, MG-262, piceatannol, PP2, carbacylin, Suc-Leu-Leu-Val-Tyr-AMC and mouse monoclonal antibody to ubiquitinated proteins (clone FK2) were from Biomol (Plymouth Meeting, PA). Tubulin, >99% pure from bovine brain, was purchased from Cytoskeleton (Denver, CO). An expression vector for the cytoplasmic domain of erythrocyte band 3 (cdb3) was a generous gift from Dr. Phillip Low (Purdue University, West Lafayette IN). Cdb3 was expressed in E. coli and purified on a His-select HC-nickel column. 37 SuperSignal West Pico chemiluminescent substrate was from Pierce (Rockford, IL). Convulxin was purified according to the method of Polgar et al. 31 Collagen, Type I; equine tendon, was from Chronolog (Havertown, PA). Collagen-related peptide (CRP) was a gift from Dr. Todd Quinton. SC57101 was a gift from Searle Research and EDTA, 1mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 100 µM PMSF, 1 µg/ml pepstatin and 10 µg/ml leupeptin) and NP-40 lysis buffer (the above lysis buffer in the absence of SDS and deoxycholate). Samples were kept on ice for 10 minutes to ensure total lysis and centrifuged 10 minutes/12,000g/4 o C to remove debris.
Preparation of Mouse Platelets
Blood was collected from the vena cava of anesthetized mice into syringes containing 1/10 blood volume of 3.8% sodium citrate as anticoagulant. Red blood cells were separated by centrifugation at 100 g for 10 min. Platelet-rich plasma was removed, and the platelet pellet was resuspended in Tyrode's buffer (pH 7.4) containing 0.05 U/ml apyrase. were separated and transferred as described above. Membranes were exposed overnight to a Phosphor screen and bands visualized by a Packard Cyclone Storage Phosphor System. Densities were calculated with Image Gauge software. Membranes were then probed for Syk as described above.
Assay of Platelet proteasomal activity
Proteasome activity was assayed spectrofluorimetrically using Suc-Leu-Leu-Val-Tyr-AMC as a substrate. 38, 39 Assay buffer ( 20mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8)
and Suc-Leu-Leu-Val-Tyr-AMC (25µM) in DMSO were added to a cuvette and placed in the were washed twice in HEPES-Tyrode's buffer, pH 6.5, containing 100 mu/ml apyrase and 100 nM carbacyclin.. Platelets were pelleted and lysed in 10mM HEPES, 150mM NaCl, pH 7.7 containing 0.1% Triton and 1mM EGTA.
Results:
Since c-Cbl has been shown to be present in platelets and is thought to be a negative In order to determine whether ubiquitination of Syk is a general phenomenon downstream of all platelet agonists, we stimulated platelets with thrombin, an agonist of Gq/G13-coupled PAR receptors. 41, 42 In contrast to GPVI-dependent agonists, thrombin did not cause the ubiquitination of Syk whether the platelets aggregated or aggregation was prevented by a fibrinogen receptor antagonist, SC57101A ( Figure 2B ). We saw no evidence of ubiquitination whether we probed either for phosphotyrosine, ubiquitin, or Syk. Syk tyrosine phosphorylation is induced by thrombin but to a significantly lesser extent than convulxin (about 2 fold compared to about 40 fold). This result suggests that Syk has to be activated prior to ubiquitination since thrombin minimally activates Syk. We have found that tyrosine phosphorylation of Syk occurs more rapidly than ubiquitination since 5 sec after convulxin addition, tyrosine phosphorylation is evident in the absence of ubiquitination (data not shown).
Syk activation through the collagen receptor is downstream of Src-family kinases. 36 Hence we used the Src-family kinase inhibitor PP2 to test whether activation of Syk is required for ubiquitination. Figure 2C shows that PP2 completely blocked ubiquitination of Syk. Syk phosphorylation was inhibited as well ( Figure 2C-2) . SU6656, another Src kinase inhibitor, had a similar effect while PP3, the control for PP2, had no effect.
The role of ubiquitination in the production of protein degradation by the proteasome is well established. 28, 29 Ubiquitinated Syk is degraded some immune and cultured cells.
35,43
Therefore we used several different proteasomal inhibitors to test whether ubiquitination primed Syk for degradation (Figure 3-A) . When platelets were preincubated with the proteasome inhibitor epoxomicin and stimulated with the GPVI agonist, convulxin, an increase in ubiquitinated Syk was not observed. An increase in ubiquitinated Syk would indicate that Syk is degraded by the proteasome. We also did the same experiment with collagen or CRP, with differing preincubation times and using PRP for inhibitor preincubation rather than washed platelets and obtained no essential difference in the final results. Similar results were obtained with MG132 (20 µM) and MG262 (1 µM) alternative proteasome inhibitors (data not shown). To prove that these inhibitors actually entered the platelet and inhibited platelet proteasomal enzymes, we incubated platelets with proteasomal inhibitors, washed the platelets, lysed them and tested the proteasomal activity of the lysate using a fluorogenic proteasomal substrate N-
The results shown in figure 3 -B demonstrate that both epoxomicin and MG262 enter the platelet and inhibit proteasomal enzymes. Epoxomicin inhibited activity by 100% and
MG262 inhibited by greater than 80%. The greater inhibition of epoxomicin is probably due to the fact that it is an irreversible inhibitor. Proteasomal degradation of ubiquitinated Syk is more likely to target active Syk exclusively rather than the bulk Syk. 35, 40, 43 To assess this possibility, Chloroquine also did not change the levels of ubiquitinated Syk in either collagen (Figure 4-B) or convulxin-stimulated platelets (not shown).
Since we could not demonstrate an effect of ubiquitination on the catabolism of Syk, we decided to test whether the enzymatic activity of Syk was affected by ubiquitination. FK2 is an antibody capable of immunoprecipitating polyubiquitinated proteins. Figure 4 ). We assessed the activity of ubiquitinated Syk in an in vitro kinase assay using tubulin as substrate.
Tubulin has been shown to be a selective substrate for Syk and ZAP70 as compared to Srcfamily kinases 44 . In order to demonstrate the lack of interference by Src-family kinases in our assay, we tested the ability of tyrosine kinase inhibitors PP2 and piceatannol to inhibit the kinase activity found in an FK2 immunoprecipitate of convulxin activated platelets ( Figure 5 ; Panel A).
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The phosphorylation of tubulin by this fraction was inhibited by the Syk inhibitor, piceatannol but not by the Src-family kinase inhibitor PP2. Figure 5 ; Panel B compares the activity of total Syk to the FK2 ubiquitinated fraction. Activity was measured as the ability of each fraction to incorporate [ 32 P]-PO 4 into tubulin divided by the immunostaining density of the fraction to assess specific activity. The activity in the ubiquitinated fraction was determined to be higher than the total Syk fraction. In order to compare similar levels of protein, the total Syk was diluted 10-fold to obtain the same immunostaining as seen in the FK2 fraction. The specific activity of the diluted Syk was the same as the undiluted Syk confirming the linearity of the assay. We used three different antibodies to immunoprecipitate Syk: a monoclonal to linker region between the C-terminal SH2 domain and the kinase domain (4D10, Santa Cruz), a polyclonal raised against the N-terminus of Syk (N19, Santa Cruz) and a polyclonal we raised against the N-terminal SH2
domain. All three antibodies gave similar results. Similar results were also obtained when cdb3,
another substrate with Syk specificity, was used in this assay 37 (data not shown).
A possible explanation for the apparent higher activity of the ubiquitinated Syk is that ubiquitination of Syk requires its activation and thus a greater proportion of the ubiquitinated Syk is in the activated state. Immunoblotting for total tyrosine phosphorylation does not show a dramatic increase in the ubiquitinated fraction of Syk is enriched for tyrosine-phosphorylated Syk (Figure 2 ; Panel A-3). However, overall tyrosine phosphorylation is a poor assessment of Syk activity since Syk has numerous tyrosine phosphorylation sites that show no detectable effect on its activity 45 . In order to determine the amount of active Syk in each fraction, we used a specific antibody to the phosphorylated tyrosines 525/526 of the activation loop. 46 The results of these experiments, shown in Figure 6A , demonstrate that ubiquitinated Syk makes up the majority of the Syk that is phosphorylated on tyrosines 525/526. When specific kinase activity is In order to establish a role for c-Cbl in the ubiquitination of Syk, we compared the ubiquitination patterns for Syk in wild type and c-Cbl knockout mice. Figure 7 shows that wild type mice show a similar pattern of Syk ubiquitination as seen in human platelets. There is no ubiquitination in the sample from the mouse platelets deficient in c-Cbl. However, consistent with previous results 34 , Syk appears to be more heavily phosphorylated in the sample from the knockout mouse platelets as compared to the control. (The ratio of pY staining to Syk staining is 6.7 for WT versus 8.9 for knockout in the 1 min sample). Aggregation in the c-Cbl deficient platelets to convulxin is enhanced as has been demonstrated by Auger et al. 34 More important, the level of phospho-Syk decreases after 4 mins in the wild type murine platelets. In contrast, the level of phospho-Syk in the c-Cbl deficient platelets does not decline and appears to increase, It is likely that these levels represent the inability phosphatases to interact with Syk in c-Cbl deficient platelets.
Discussion
The importance of Syk activation downstream of the collagen receptor of platelets is well established. It has been shown that the tandem SH2 domains of Syk interfere with Ca 2+ mobilization by CRP in megakaryocytes. 36 Syk-deficient megakaryocytes also show a defect in GPVI-dependent Ca 2+ mobilization. The presence of c-Cbl in platelets and its agonist-dependent phosphorylation are well also established. 30, 31 Our study confirms the fact that there is a direct interaction of these two important signaling molecules in platelets. 32 The interaction of Syk and c-Cbl has several potential functions in cellular signaling. c-Cbl may play a role in promoting signaling pathways by bringing important signaling molecules together. 15 Phosphorylation of Cterminal tyrosines of c-Cbl by Syk and/or other kinases promotes its interaction with Src-family tyrosine kinases and other proteins involved in collagen receptor-induced signaling such as PI-3 kinase p85 subunit. 18, 20 c-Cbl is an E3 ligase and platelets contain both ubiquitin and ubiquitin conjugating enzymes 47 . Therefore, in this study we wished to determine whether Syk in platelets is ubiquitinated in response to activation of collagen-dependent signaling. We have found that Syk is ubiquitinated in platelets activated with agonists that activate the GPVI-dependent pathway.
Most previous studies of Syk in platelets have either not directly considered ubiquitination of Syk or have indicated that it does not occur. 34 However, in many studies bands can be seen above Syk consistent with a ubiquitination pattern. 9, 46 In this study we have detected ubiquitination of Syk using several independent approaches in response to GPVI-activating agonists but not to thrombin, an agonist that activates a guanine nucleotide binding proteincoupled receptor. It is hard to determine whether this is an inherent property of this agonist or due to fact that the level of Syk activation is about 20 fold lower with thrombin. The fact that Syk activation is required for ubiquitination argues for the latter explanation ( Figure 2C ). It is possible that thrombin causes a low level of ubiquitination that we have not been able to detect.
The experiments with the c-Cbl knockout mice demonstrate the importance of c-Cbl to the ubiquitination of Syk in platelets which is consistent with studies in other cells. 40 For
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The pattern of Syk ubiquitination in platelets is virtually identical to that described in nucleated cells activated via multichain immunorecognition receptors 40 . A major difference with these studies is the fact that proteasomal degradation inhibitors blocked the proteolysis of ubiquitinated Syk in nucleated cells. We failed to find an effect of either proteasomal or lysosomal inhibitors on the ubiquitination patterns. In fact it appears that Syk is not degraded after platelet activation (for example see Figures 2A panel 2 or Figure 3 ). This is somewhat surprising in light of reports that proteasomes are present in platelets 38 . It is possible that a small fraction of ubiquitinated Syk is degraded but this may have no physiological significance. The fact that Syk may be ubiquitinated but not catabolized by the proteasome is not unprecedented.
Fgr has been shown to be di-ubiquitinated in neutrophils adhering via a 2 integrin but no apparent degradation of the protein was detected 48 .
Since c-Cbl has been proposed to be a negative regulator of platelet function 34 , we hypothesized that ubiquitination might inhibit the activity of Syk. In order to test this hypothesis, separation of Syk into ubiquitinated and ubiquitin-depleted fractions was accomplished by the use of the FK2 antibody. It was surprising to find that the ubiquitinated fraction appeared to have a higher specific activity than the total Syk. A possible explanation for this is that, since Syk needs to be activated prior to ubiquitination, a greater fraction of ubiquitinated Syk would be active compared to nonubiquitinated Syk. We have used a phosphospecific antibody to the phosphorylated activation loop in Syk to assess Syk's activation status and determined that a substantial portion of Syk (60-75%) phosphorylated on the tyrosines of the activation loop was ubiquitinated. This data is supported by Rao et al 35 , who showed that the presence of active Cbl did not influence the kinase activity of Syk.
Although degradation of ubiquitinated Syk has not been detected in our system, ubiquitination may regulate the activity of Syk in platelets through degradation-independent mechanisms. Ubiquitination has been shown to regulate the interaction of many intracellular proteins. For example, in the cascade that leads to I B kinase activation downstream from several immune receptors, ubiquitination facilitates the interaction between two intermediate regulators, TRAF6 and TAB2. 49 In other circumstances, ubiquitination has been shown to block the interaction of proteins. Ubiquitination of the p85 subunit of PI 3-kinase blocks its interaction with the T-cell receptor and CD28. 50 Furthermore, ubiquitination can change the subcellular localization of proteins. Thus ubiquitination of Syk may prevent its interaction with some of its downstream targets by directly blocking this interaction or translocating them to a compartment where Syk can not phosphorylated them. Syk activation occurs more rapidly than ubiquitination allowing a signal through that could be dampened by ubiquitination.
The fact that we found Syk to be more heavily phosphorylated in the c-Cbl knockout mice confirms the observations of Auger et al. 34 This suggests that, in addition to ubiquitination, the level of Syk tyrosine phosphorylation may depend on an interaction with c-Cbl. We also confirmed the fact that c-Cbl deficient platelets show more robust aggregation. We show in this paper that while ubiquitinated Syk from wild type platelets is dephosphorylated, in the c-Cbl deficient cells dephosphorylation does not appear to occur. Thus, we speculate that the interaction with c-Cbl is necessary for the interaction between Syk and its phosphatase.
Interaction of c-Cbl and phosphatases has been proposed. 51, 52 We cannot say whether it is the ubiquitination itself that is important or just that c-Cbl acts as a scaffold to bring the phosphatase to Syk. This hypothesis would explain the observation of Auger et al. 34 and ourselves that c-Cbl is a negative regulator of Syk function.
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Ubiquitination appears to be a consequence of the interaction of Syk with c-Cbl. Ubiquitination does appear to cause enhanced degradation either through proteosome or lysosome-dependent pathways. Ubiquitinated Syk appears to exhibit elevated specific activity, but this increase is entirely due to the enrichment of the ubiquitinated fraction for activation loop phosphorylated and thus activated Syk. Indeed, more than 50% of activated Syk is ubiquitinated. Thus ubiquitination may modulate Syk by yet to be discovered interactions. We suggest that one possible mechanism is that interaction with c-Cbl is essential to dephosphorylate Syk and thus provides an off switch. for their kinase activity as in figure 5 . The relative protein mass in each fraction was assessed from immunoblots using the phosphospecific antibody for Syk residues pY525/pY526.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Figure 7 . Aggregation and Syk activation in wild type (+/+) and c-Cbl knockout (-/-) murine platelets. Washed murine platelets were activated for indicated times with 100 ng/ml convulxin (arrow). Aggregation tracings are shown on the left (the arrow indicates addition of convulin), Syk was immunoprecipitated as described and immunoblots were probed for phosphotyrosine. This antibody was stripped from the blot and reprobed for Syk.
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